Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareBOM:530549 -2.88%76 Gross Margin % is 67.51% as of Mar. 2026, which is 3% above its 10-year median of 65.43. GuruFocus rates BOM:530549 with a GF Score™ of 76/100 and a GF Value™ of ₹387.34 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Shilpa Medicare ranks better than 81.76% on this metric.
The historical rank and industry rank for Shilpa Medicare's Gross Margin % or its related term are showing as below:
BOM:530549'
s Gross Margin % Range Over the Past 10 Years
Min: 49.06 Med: 65.43 Max: 70.08
Current: 70.07
During the past 13 years, the highestGross Margin % of Shilpa Medicare was 70.08%. The lowest was 49.06%. And the median was 65.43%.
BOM:530549's Gross Margin % is ranked better than 81.76% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:530549: 70.07
Shilpa Medicare had a gross margin of 67.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Shilpa Medicare was 0.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Shilpa Medicare had a gross margin of 67.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Shilpa Medicare Gross Margin % Related Terms
Shilpa Medicare Gross Margin % Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530549 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Shilpa Medicare (BOM:530549) has a Gross Margin % of 67.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Shilpa Medicare and its competitors. This is near median its historical median of 65.43. Over the past decade, Shilpa Medicare's Gross Margin % has ranged from 49.06 to 70.08. According to the industry distribution chart, Shilpa Medicare ranks #172 out of 943 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Shilpa Medicare's Gross Margin % too high?
Shilpa Medicare's current Gross Margin % of 67.51% is near median its 10-year median of 65.43. Over the past 10 years, this metric has ranged from a low of 49.06 to a high of 70.08. The Drug Manufacturers industry median Gross Margin % is 48.54. Shilpa Medicare's value of 67.51% is 39.1% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #172 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #172 out of 943 companies for Gross Margin %. This places Shilpa Medicare in the top 18% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Shilpa Medicare's value of 67.51% is 39.1% above this benchmark. Historically, Shilpa Medicare's own Gross Margin % has ranged from 49.06 to 70.08 over the past decade. While the company's 10-year median is 65.43 vs. the industry median of 48.54, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current Gross Margin % of 67.51% is 39.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Gross Margin % is 67.51%, which is near median its own 10-year median of 65.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (BOM:530549) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.34, compared to a current price of ₹619.55 — trading 59.9% above its estimated fair value. The current Gross Margin % is 67.51%, which is near median its 10-year median of 65.43 and 39.1% above the Drug Manufacturers industry median of 48.54. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Shilpa Medicare (BOM:530549), the current Gross Margin % is 67.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (BOM:530549) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹619.55 is trading 59.9% above its estimated GF Value™ of ₹387.34.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for BOM:530549:
Gross Margin %: 67.51% (near median its 10-year median of 65.43)
GF Value™: ₹387.34 vs. price of ₹619.55 (59.9% above fair value)
Industry Position: 39.1% above the Drug Manufacturers median (#172 of 943)
No single metric tells the full story. See the BOM:530549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for BOM:530549
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530549 has been successfully added to your 
